Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249509 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT00249509 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 132 participants.
The verdict
NCT00249509, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
Recent research has identified the following withdrawal symptoms to be associated with abruptly stopping marijuana use: anxiety, irritability, bodily aches and pains, and difficulty sleeping. These symptoms resemble those of both depression and nicotine withdrawal, suggesting that a similar treatment drug may be useful. This study will evaluate the effectiveness of two antidepressant drugs, bupropion and nefazodone, in reducing withdrawal symptoms in marijuana dependent individuals.
Interventions
- DRUG Bupropion
- DRUG Nefazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2000-09 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249509
The ClinicalTrials.gov registry entry for NCT00249509 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupropion is the first listed.
NCT00249509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249509 about?
NCT00249509 is a clinical study titled "Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals". Recent research has identified the following withdrawal symptoms to be associated with abruptly stopping marijuana use: anxiety, irritability, bodily aches and pains, and difficulty sleeping. These symptoms resemble those of both depression and nicotine withdrawal, suggesting that a similar treatmen...
What is the current status of trial NCT00249509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2000-09. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00249509?
The interventions under investigation include: Bupropion (DRUG), Nefazodone (DRUG).
Who is sponsoring clinical trial NCT00249509?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.